Comparison of the performance of anti‐CD7 and anti‐CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T‐cell acute lymphoblastic leukemia cell line
- 1 January 1995
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 13 (4) , 185-200
- https://doi.org/10.1002/hon.2900130403
Abstract
We have investigated the cytotoxic performance of two different anti-CD7/anti-saporin BsAb's (HB2 × DB7-18 and Q1.1), three anti-CD38/anti-saporin BsAb's (OKT10 × RabSap, OKT10 × DB7-18 and Q4.1) and an anti-CD7 (HB2-Sap) and anti-CD38-saporin (OKT10-Sap) immunotoxin for delivering the ribosome inactivating protein (rip) to the human T-cell acute lymphoblastic leukemia cell line HSB-2. In the case of CD7 as target molecule the immunotoxin outperformed both anti-CD7 BsAb's being six times more effective than HB2 × DB7-18 and 98 times more so than Q1.1 at effectively inhibiting protein synthesis in a dose dependent manner. The chemically constructed HB2 × DB7-18 BsAb was more effective at inhibiting protein synthesis and cell growth in target HSB-2 cells in a dose dependent manner than the quadroma produced BsAb Q1.1. Both BsAb demonstrated a prozone effect used at concentrations above 0.1 nM though this was more pronounced for Q1.1 than for HB2 × DB7-18. The prozone effect was partially though not completely reversed by increasing the concentration of saporin in the system. In the case of CD38 as target molecule the anti-CD38 IT OKT10-Sap performed poorly, never actually achieving its IC50. Two BsAb's constructed with monoclonal anti-saporin Fab arms each recognizing a different epitope on the saporin molecule also performed poorly. IN contrast the BsAb OKT10 × RabSap constructed with Fab derived from a rabbit polyclonal anti-saporin antiserum performed in a dose dependent manner achieving its IC50 at a concentration of 1.3 nM. This BsAb also exhibited a prozone effect. These results exemplify the importance of cross linking adjacent target molecules on the cell surface in order to achieve effective delivery of saporin to the cell interior.Keywords
This publication has 18 references indexed in Scilit:
- Therapy of human B‐cell lymphoma bearing scid mice is more effective with anti‐CD19‐and anti‐CD38‐saporin immunotoxins used in combination than with either immunotoxin used aloneInternational Journal of Cancer, 1995
- Therapy of human T‐cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti‐CD7‐saporin immunotoxins containing hindered or non‐hindered disulphide cross‐linkersInternational Journal of Cancer, 1994
- Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) AntibodyNew England Journal of Medicine, 1993
- Bifunctional antibodies: concept, production and applicationsBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1990
- Evaluation of four CD22 antibodies as ricin a chain‐containing immunotoxins for the in vivo therapy of human B‐cell leukemias and lymphomasInternational Journal of Cancer, 1988
- Biodistribution and tumour localisation of a daunomycin-monoclonal antibody conjugate in nude mice with human tumour xenograftsCancer Immunology, Immunotherapy, 1988
- Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibodyCancer Immunology, Immunotherapy, 1987
- Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins.Journal of Biological Chemistry, 1985
- Ribosome-inactivating proteins from the seeds of Saponaria officinalis L. (soapwort), of Agrostemma githago L. (corn cockle) and of Asparagus officinalis L. (asparagus), and from the latex of Hura crepitans L. (sandbox tree)Biochemical Journal, 1983
- The question of stemlines in human acute leukemiaExperimental Cell Research, 1970